Theriva Biologics Inc (TOVX)
1.68
-0.05
(-2.89%)
USD |
NYAM |
Jan 07, 15:34
Theriva Biologics SG&A Expense (Quarterly): 2.302M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co Inc | 2.731B |
| Pro-Dex Inc | 1.294M |
| NovaBay Pharmaceuticals Inc | 2.65M |
| Palatin Technologies Inc | 2.021M |
| iBio Inc | 2.801M |